QT
CMPX icon

Quantbot Technologies’s Compass Therapeutics CMPX Stock Holding History

Quantbot Technologies’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.81K Buy
+720
New +$4.16K ﹤0.01% 1588
2023
Q2 		– Sell
-17
Closed -$56 – 1623
2023
Q1 		$56 Buy
+17
New +$67 ﹤0.01% 1483

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Quantbot Technologies's CMPX Position: Q1 2026 in Review

Quantbot Technologies opened a new position in Compass Therapeutics (CMPX) in Q1 2026: 720 shares worth $3.81K. The stake represents ﹤0.01% of the portfolio and ranks #1588 among its holdings. This is a return to the name: Quantbot Technologies previously reported a position in CMPX as recently as Q1 2023.

Quantbot Technologies first reported a position in CMPX in Q1 2023 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Quantbot Technologies held 720 shares of Compass Therapeutics worth $3.81K as of Q1 2026.
  • Compass Therapeutics was a new Quantbot Technologies position in Q1 2026.
  • Compass Therapeutics made up ﹤0.01% of Quantbot Technologies's portfolio in Q1 2026, its #1588 holding.
  • Quantbot Technologies first reported a position in Compass Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.